Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/JuhATCOqI1A/235842.php
Wednesday, 12 October 2011
Talactoferrin Phase II Trial In Non-Small Cell Lung Cancer Shows Promise
Data from a Phase II randomized, double-blind, placebo-controlled clinical trial which assessed talactoferrin (an oral immunotherapy) in individuals who had previously received treatment for non-small cell lung cancer (NSCLC) has been published and will appear in the November 1, 2011 print issue of the peer-reviewed medical journal, Journal of Clinical Oncology, Agennix AG ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment